Bayer - Recruiting N/A to 12 years. - A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A.
CSL Behring - Recruiting N/A to 11 years. - A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostater) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (ó 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors).
Bayer - Recruiting N/A to 12 years. - A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy.
Novo Nordisk - Recruiting N/A to 11 years. - A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A.
Bayer - Recruiting 18 years or older. - Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis.
Octapharma - Recruiting 18 years or older. - Prospective, Open-label, Multicenter Phase 3b Study to Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A.
Green Cross Corporation - Recruiting 12 years or older. - Determination of Safety, Efficacy and Pharmacokinetics of GreenGeneT F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A.
GreenGeneT F and an approved recombinant Factor VIII product; GreenGeneT F
CSL Behring - Recruiting N/A to 11 years. - A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B.